| Identification | Back Directory | [Name]
2,4,6-Quinazolinetriamine, N6-[(3,4-dichlorophenyl)methyl]- | [CAS]
13794-65-5 | [Synonyms]
AI352841
Pam 1392
AI3-52841
AI3 52841
2,4,6-Quinazolinetriamine, N6-[(3,4-dichlorophenyl)methyl]- | [Molecular Formula]
C15H13Cl2N5 | [MOL File]
13794-65-5.mol | [Molecular Weight]
334.2 |
| Hazard Information | Back Directory | [Description]
Pam 1392 is a chemotherapeutic agent. | [Uses]
PAM 1392 is active orally against Plasmodium berghei in mice, P. cynofologi and P. knowlesi in monkeys and Trypanosoma cruzi in tissue cultures of mice, and hemolytic streptococci in vitro. PAM 1392 has antimalarial and antitrypanosomal activities, which is proming for rasearch of drug-resistant malaria[1][2]. | [References]
[1] Shepard CC. Further experience with the kinetic method for the study of drugs against Mycobacterium leprae in mice. Activities of DDS, DFD, ethionamide, capreomycin and PAM 1392. Int J Lepr Other Mycobact Dis. 1969 Oct-Dec;37(4):389-97. PMID:4918202
[2] Thompson PE, et al. PAM 1392 (2,4-diamino-6-(3,4-dichlorobenzylamino) quinazoline) as a chemotherapeutic agent: Plasmodium berghei, P. cynomolgi, P. Exp Parasitol. 1969 Aug;25(1):32-49. DOI:10.1016/0014-4894(69)90050-2 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|